• Topbanner

    Scientific Advisors


Scientific Advisors


Jeremy Ruskin Prof. Jeremy Ruskin, MD


More info

Dr. Jeremy Ruskin is Professor of Medicine at Harvard Medical School and Founder and Director Emeritus of the Cardiac Arrhythmia Service at Massachusetts General Hospital. Dr. Ruskin received his undergraduate degree summa cum laude from Tufts University in 1967 and his medical degree cum laude from Harvard Medical School in 1971.

In 1978, Dr. Ruskin founded the MGH Cardiac Arrhythmia Service and Clinical Electrophysiology Laboratory, the first subspecialty service dedicated to the care of patients with cardiac arrhythmias in New England and one of the first in the United States.

Dr. Ruskin served as a member of the FDA Cardiovascular and Renal Drugs Advisory Committee for 5 years and as a consultant to the National Center for Health Services Research and Health Care Technology Assessment.

For the past 25 years, he has worked extensively on the scientific and regulatory aspects of medical device and drug development as well as cardiovascular drug safety. In 1996, Dr. Ruskin founded the Annual International Atrial Fibrillation Symposium which he has directed since its inception and is the largest and longest running free-standing academic meeting on atrial fibrillation worldwide.

Dr. Ruskin is an author of more than 450 original scientific publications, chapters, reviews, guidelines and monographs. Dr. Ruskin also maintains an active regional, national and international referral practice in the field of cardiac arrhythmias and electrophysiology and is recognized annually in Best Doctors in America and Best Doctors in Boston.

Dr. Ruskin is the recipient of the 1997 Michel Mirowski Award for Excellence in Clinical Cardiology and Electrophysiology, the 2002 Heart Rhythm Society Pioneer in Pacing and Electrophysiology Award and the 2015 KCHRS Pioneer in Electrophysiology Award. He was named the inaugural incumbent of the Omran Alomran Endowed Chair in Cardiology at Massachusetts General Hospital in 2016.


Christian Torp-Pedersen Prof. Christian Torp-Pedersen, MD, DMSc


More info

Dr. Christian Torp-Pedersen, is Professor of Cardiology at Aalborg University Hospital and has conducted clinical trials on several antiarrhythmic drugs approved during the last 20 years. His list of original research publications in peer-reviewed international journals exceeds 400, including articles in the New England Journal of Medicine and The Lancet.


Göran Duker Dr. Göran Duker, PhD


More info

Dr Göran Duker has a background as Senior Principal Scientist in Disease Area Arrhythmia at AstraZeneca, Sweden (retired 1st September 2012). He holds a PhD in experimental cardiac electrophysiology and worked 30 years on drug discovery and development within the arrhythmia field. Further he has about 50 publications on cardiovascular electrophysiology and pharmacology published in peer-review journals.


Bob Humphries Bob Humphries


More info

Bob Humphries is a pharmacologist with 30+ years of pharma experience (Fisons, Astra and AstraZeneca) as scientific and cross functional project team leader. He led teams in discovery and early progression of the marketed anti-thrombotics Brilinta and Cangrelor and cross functional teams responsible for early development of AZ bronchodilator and GR agonist projects. As VP of Inhaled Projects in AZ Respiratory and Inflammation, he was responsible for maintaining project delivery and overall strategy of Inhaled Projects and was involved in partnered early development projects and successful out-licensing. Since 2012, Bob Humphries has worked as a consultant with the aim to assist project teams translate ideas to credible, achievable plans to realise potential opportunities to change patients' lives.